Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Patalganga plant received zero observation from USFDA earlier
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Visit underscores push for self-reliance in essential medical consumables and India’s ambition to become a global medtech manufacturing hub
The goal is to better support drug developers as programs move from laboratory research into clinical trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
